TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06622057: D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer

Sponsor: InnoPharmax Inc. · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 240 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$20,993,280

Rescue Site Savings

+$13,842,444

Unlock Full NCT06622057 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06622057 Rescue Dossier →